Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neos Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Neos Therapeutics, Inc. (“Neos Therapeutics” or the “Company”) (NASDAQ:NEOS)
The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, on October 19, 2015, the Company disclosed that the U.S. Food and Drug Administration had identified deficiencies in the Company's new drug application for Cotempla XR-ODT that precluded discussion of labeling and marketing requirements at that time. In addition, on August 11, 2016, the Company announced its financial results for its second quarter of 2016, reporting it had missed its earnings expectations by $0.49 per share. As a result of these disclosures, Neos Therapeutics’ stock price has significantly declined.
If you invested in Neos Therapeutics’ common stock or options and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Neos Therapeutics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.
* The submission of this form does not create an attorney-client relationship.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.